Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wix.Com Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M), while Wix.Com Ltd trades at $66.47 (market cap $2.79B). The key difference: Wix.Com Ltd is far larger — about 5.5× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | WIX | |
|---|---|---|
Market Cap | $505.73M | $2.79B |
Sector | Health | Technology |
52-Week High | $16.14 | $184.24 |
52-Week Low | $5.48 | $40.43 |
Enterprise Value | $607.68M | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Wix trades at $62.43, up 3.7% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in three of the last four quarters, while revenue grew to $1.99B in 2025. The stock faces headwinds from a class action lawsuit following a Q1 2026 miss and a 27% price drop in May 2026.
The outlook is cautiously optimistic given Wall Street's $79.75 price target and 66% buy ratings, but litigation over financial disclosures and negative shareholder equity pose significant risks. Revenue growth remains a key catalyst, though profitability volatility requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
